BioCardia Faces Delisting Concerns

TL;DR

BioCardia might get delisted, check their listing status.

AI Summary

BioCardia, Inc. filed an 8-K on September 24, 2025, to report a notice of delisting or failure to meet continued listing standards. The company is based in Sunnyvale, California, and its former names include Tiger X Medical, Inc. and Cardo Medical, Inc.

Why It Matters

This filing indicates potential issues with BioCardia's ability to remain listed on its exchange, which could impact its stock liquidity and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet continued listing standards is a significant event that can lead to stock price volatility and reduced trading.

Key Players & Entities

• BioCardia, Inc. (company) — Registrant
• Tiger X Medical, Inc. (company) — Former Company Name
• Cardo Medical, Inc. (company) — Former Company Name
• September 24, 2025 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 B — ch registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat
• $2,500,000 — ockholders' equity had fallen below the $2,500,000 required minimum for continued listing
• $1.905 — mon stock at an exercise price equal to $1.905 per share, which are exercisable at any
• $719,000 — e net proceeds from such financing were $719,000 after deducting fees and expenses. On
• $1.95 — mon stock at an exercise price equal to $1.95 per share, which are exercisable at any
• $529,000 — e net proceeds from such financing were $529,000 after deducting fees and expenses. On
• $1.25 — n stock at a combined offering price of $1.25 per share and warrant pursuant to secur
• $5.1 million — from such financing were approximately $5.1 million after deducting placement agent fees an
• $2 — mmon stock at an average share price of $2.55, resulting in net proceeds of $1.0 m
• $1.0 million — of $2.55, resulting in net proceeds of $1.0 million after deducting fees and expenses. As
• $2.5 million — as regained compliance with the minimum $2.5 million stockholders' equity requirement for co

Filing Documents

• bcda20250923_8k.htm (8-K) — 27KB
• 0001437749-25-029768.txt ( ) — 155KB
• bcda-20250924.xsd (EX-101.SCH) — 3KB
• bcda-20250924_def.xml (EX-101.DEF) — 11KB
• bcda-20250924_lab.xml (EX-101.LAB) — 15KB
• bcda-20250924_pre.xml (EX-101.PRE) — 11KB
• bcda20250923_8k_htm.xml (XML) — 3KB

01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed on that certain Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on April 4, 2025 (the "Original 8-K"), on April 1, 2025, BioCardia, Inc. (the "Company," "we," "us" and "our") received a notification letter (the "Notice") from the Nasdaq Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that its amount of stockholders' equity had fallen below the $2,500,000 required minimum for continued listing set forth in Nasdaq Listing Rule 5550(b)(1). As noted in the Original 8-K, the Company had until May 16, 2025 to provide Nasdaq with a specific plan to achieve and sustain compliance. The Company submitted its plan to regain compliance on May 15, 2025, and on June 24, 2025, received written notice that, based on review of the compliance plan, the Nasdaq staff granted the Company an extension to September 29, 2025 to regain compliance with the Rule. The Company is filing this Current Report on Form 8-K (this "Report") to provide an update to its compliance with continued listing requirements as set forth in Nasdaq Listing Rule 5550(b)(1). On April 22, 2025, we entered into a Securities Purchase and Registration Rights Agreement relating to a private placement with certain qualified institutional buyers and institutional accredited investors, as well as certain members of our board of directors and executive officers, which closed on April 23, 2025. Pursuant to the agreement, we sold 406,818 shares of our common stock and warrants to purchase an aggregate of 406,818 shares of our common stock at an exercise price equal to $1.905 per share, which are exercisable at any time before the earlier of April 24, 2030 or the approval by the Japanese Pharmaceuticals and Medical Devices Agency of our application of our CardiAMP Cell Therapy System. The ne

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not purely historical regarding the Company's or its management's intentions, beliefs, expectations and strategies for the future, including statements regarding the Company's regaining and maintaining compliance with Nasdaq listing standards. All forward-looking statements included in this Current Report on Form 8-K are made as of the date of this report, based on information currently available to the Company. The risks and uncertainties that may cause actual results to differ materially from the Company's current expectations are more fully described in the Company's Annual Report on Form 10-K filed with the SEC on March 26, 2025, any subsequently filed Quarterly Reports on Form 10-Q, and its other reports, each as filed with the SEC. Except as required by law, the Company assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ David McClung David McClung Chief Financial Officer Date: September 24, 2025

View Full Filing

View this 8-K filing on SEC EDGAR